#1 Clinical Trials Search in Europe

6-(Fluoro-18F)-3-(1H-Pyrrolo[2,3-C]Pyridin-1-Yl)-5-Isoquinolinamine

This article discusses the use of the drug 6-(Fluoro-18F)-3-(1H-Pyrrolo[2,3-C]Pyridin-1-Yl)-5-Isoquinolinamine, also known as florquinitau F18 or [18F]MK-6240, in clinical trials for Alzheimer’s disease. This compound is being used as a diagnostic tool to detect tau protein buildup in the brain, which is associated with Alzheimer’s disease progression. The trials aim to evaluate the effectiveness of potential treatments for early-stage Alzheimer’s disease and to monitor disease progression using this innovative imaging technique.

Table of Contents

Introduction

Alzheimer’s disease is a progressive brain disorder that affects millions of people worldwide. Researchers are constantly working to develop new tools and treatments to better understand and combat this devastating condition. One such tool that has shown promise in recent studies is a compound with a long and complex name: 6-(FLUORO-18F)-3-(1H-PYRROLO[2,3-C]PYRIDIN-1-YL)-5-ISOQUINOLINAMINE. While this name might seem intimidating, this article will break down what this compound is and why it’s important for patients and families affected by Alzheimer’s disease.

What is 6-(FLUORO-18F)-3-(1H-PYRROLO[2,3-C]PYRIDIN-1-YL)-5-ISOQUINOLINAMINE?

6-(FLUORO-18F)-3-(1H-PYRROLO[2,3-C]PYRIDIN-1-YL)-5-ISOQUINOLINAMINE is a specialized imaging agent used in medical research. It’s also known by several other names, including:

  • Florquinitau F18
  • [18F]MK-6240
  • MK-6240
These names are easier to pronounce and remember, so you might hear doctors or researchers use them instead of the full chemical name.[1][2][3]

How Does It Work?

This compound is what’s known as a tau PET tracer. Here’s what that means:

  • Tau is a protein that can build up abnormally in the brains of people with Alzheimer’s disease.
  • PET stands for Positron Emission Tomography, which is a type of brain imaging scan.
  • A tracer is a substance that can be detected by imaging equipment.
When injected into a patient, florquinitau F18 binds to tau proteins in the brain. This allows researchers to see where and how much tau has accumulated using a PET scanner. This information is crucial for understanding the progression of Alzheimer’s disease and evaluating potential treatments.[1][2]

Uses in Alzheimer’s Disease Research

Florquinitau F18 is primarily used in research studies focusing on Alzheimer’s disease. It helps researchers in several ways:

  1. Diagnosis: It can help identify tau buildup in the brain, which is a hallmark of Alzheimer’s disease. This can aid in early diagnosis, even before symptoms appear.
  2. Disease Progression: By tracking changes in tau levels over time, researchers can better understand how Alzheimer’s disease progresses.
  3. Treatment Evaluation: It allows researchers to see if potential new treatments are effective in reducing tau buildup in the brain.
This imaging agent is particularly useful for studying people with early Alzheimer’s disease or those at risk of developing the condition.[1][2][3]

Current Clinical Trials

Florquinitau F18 is currently being used in several clinical trials to study Alzheimer’s disease and potential treatments. Some notable studies include:

  • A study evaluating the effects of an anti-tau monoclonal antibody called JNJ-63733657 in patients with early Alzheimer’s disease.[1]
  • A trial assessing the efficacy and safety of a drug called BIIB080 in people with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease dementia.[2]
  • A study investigating a phosphorylated tau targeted active immunotherapy (JNJ-64042056) in participants with preclinical Alzheimer’s disease.[3]
In these trials, florquinitau F18 is used to measure changes in tau levels in the brain, helping researchers understand if the treatments being tested are effective.

How is it Administered?

Florquinitau F18 is administered as a solution for injection. It’s typically given through intravenous use, which means it’s injected directly into a vein. The dose is measured in units called megabecquerels (MBq), which is a way of measuring radioactivity. The exact dose and frequency of administration can vary depending on the specific research study. In some cases, participants might receive up to 185 MBq in a single dose, or up to 370 MBq over a period of time.[2]

Potential Benefits

While florquinitau F18 is not a treatment for Alzheimer’s disease itself, its use in research could lead to several benefits for patients in the future:

  • Earlier Diagnosis: By detecting tau buildup before symptoms appear, it could help diagnose Alzheimer’s disease at earlier stages.
  • Better Understanding of Disease Progression: This could lead to more accurate prognoses and better planning for care.
  • Improved Treatment Development: By allowing researchers to directly see the effects of potential treatments on tau buildup, it could speed up the development of new Alzheimer’s therapies.
  • Personalized Medicine: In the future, this type of imaging might help doctors choose the most effective treatments for individual patients based on their specific tau patterns.

Conclusion

6-(FLUORO-18F)-3-(1H-PYRROLO[2,3-C]PYRIDIN-1-YL)-5-ISOQUINOLINAMINE, also known as florquinitau F18, is a valuable tool in Alzheimer’s disease research. While it’s not a treatment itself, it’s helping researchers better understand the disease and develop potential new therapies. As research progresses, this imaging agent could play a crucial role in improving diagnosis, treatment, and care for people affected by Alzheimer’s disease.

Aspect Details
Drug Name 6-(Fluoro-18F)-3-(1H-Pyrrolo[2,3-C]Pyridin-1-Yl)-5-Isoquinolinamine (florquinitau F18, [18F]MK-6240)
Primary Use Diagnostic tool in PET scans for detecting tau protein buildup in the brain
Administration Intravenous injection
Target Condition Alzheimer’s Disease (various stages)
Trial Objectives Evaluate efficacy and safety of potential treatments, assess cognitive decline, monitor tau pathology
Participant Age Range Typically 55-80 years old
Key Eligibility Criteria Specific cognitive test scores, evidence of tau pathology, absence of other neurological conditions
Primary Endpoints Changes in cognitive function scores, tau PET imaging results
Study Design Randomized, double-blind, placebo-controlled, parallel-group

FAQ

  • What is 6-(Fluoro-18F)-3-(1H-Pyrrolo[2,3-C]Pyridin-1-Yl)-5-Isoquinolinamine used for in these clinical trials? This compound, also known as florquinitau F18 or [18F]MK-6240, is used as a diagnostic tool in PET scans to detect tau protein buildup in the brain, which is associated with Alzheimer's disease progression.
  • What stages of Alzheimer's disease are being studied in these trials? The trials focus on various stages of Alzheimer's disease, including preclinical Alzheimer's disease, mild cognitive impairment (MCI) due to Alzheimer's disease, and early Alzheimer's disease.
  • How is the drug administered to patients in these trials? The drug is administered as a solution for injection, typically given intravenously (into a vein) during PET imaging procedures.
  • What are some of the main objectives of these clinical trials? The main objectives include evaluating the efficacy and safety of potential Alzheimer's treatments, assessing changes in cognitive decline, and monitoring the accumulation and propagation of tau pathology in the brain.
  • Are there any specific eligibility criteria for participants in these trials? Yes, eligibility criteria typically include age ranges (e.g., 55-80 years old), specific cognitive test scores, evidence of tau pathology on PET scans, and the absence of other neurological or psychiatric conditions that could affect cognition.

Ongoing Clinical Trials on 6-(Fluoro-18F)-3-(1H-Pyrrolo[2,3-C]Pyridin-1-Yl)-5-Isoquinolinamine

  • Study on BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer’s Disease Dementia

    Not yet recruiting

    2 1 1
    Investigated drugs:
    Belgium Czechia Denmark Finland France Germany +5

  • Study on JNJ-64042056 for Preclinical Alzheimer’s Disease in Patients

    Not yet recruiting

    2 1
    Investigated drugs:
    Belgium France Germany Spain Sweden

  • Study on the Effects of JNJ-63733657 and Florquinitau F18 in Patients with Early Alzheimer’s Disease

    Not recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Belgium France The Netherlands Spain Sweden

Glossary

  • Alzheimer's Disease (AD): A progressive brain disorder that slowly destroys memory and thinking skills, eventually affecting the ability to carry out simple tasks.
  • Tau Protein: A protein found in neurons that can form abnormal tangles in the brains of people with Alzheimer's disease, contributing to cell death and cognitive decline.
  • PET (Positron Emission Tomography): An imaging technique that uses a radioactive tracer to visualize and measure activity in different areas of the body, including the brain.
  • Florquinitau F18: A radioactive tracer used in PET scans to detect tau protein buildup in the brain, also known as [18F]MK-6240 or 6-(Fluoro-18F)-3-(1H-Pyrrolo[2,3-C]Pyridin-1-Yl)-5-Isoquinolinamine.
  • Mild Cognitive Impairment (MCI): A condition characterized by a slight but noticeable decline in cognitive abilities, including memory and thinking skills. It may progress to Alzheimer's disease in some cases.
  • Clinical Dementia Rating (CDR): A numeric scale used to quantify the severity of symptoms of dementia.
  • Mini-Mental State Examination (MMSE): A widely used test of cognitive function among older adults, evaluating orientation, attention, memory, language, and visual-spatial skills.
  • Preclinical Alzheimer's Disease: The stage of Alzheimer's disease where brain changes are occurring, but significant clinical symptoms are not yet apparent.
  • Biomarker: A measurable indicator of the presence or severity of a disease state, such as the level of tau protein in the brain for Alzheimer's disease.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare against the effects of the investigational drug.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effects-of-jnj-63733657-and-florquinitau-f18-in-patients-with-early-alzheimers-disease/
  2. http://clinicaltrials.eu/trial/study-on-biib080-for-patients-aged-50-80-with-mild-cognitive-impairment-or-mild-alzheimers-disease-dementia/
  3. http://clinicaltrials.eu/trial/study-on-jnj-64042056-for-preclinical-alzheimers-disease-in-patients/